Figure 1: miR-424(322) is in versely correlated with PD-L1 levels in ovarian cancer patients.

(a) Heat map depicting samples from TCGA 2011 combined human ovarian cancer microarray data sets that were assigned to ovarian cancer gene expression subtypes (n=489). (b) miR-424(322) levels were inversely correlated with PD-L1 (r=−0.1317, t-test, P=0.0035), PD-1 (r=−0.1215, t-test, P=0.0072), CD80 (r=−0.1148, t-test, P=0.0011) and CTLA-4 (r=−0.1, t-test, P=0.0273) expression levels in human ovarian cancer. (c) PD-L1 expression levels were positively correlated with PD-1 expression levels in human ovarian cancer (r=0.1735, t-test, P=0.0001); CD80 expression levels were positively correlated with CTLA-4 expression levels in human ovarian cancer (r=0.6530, t-test, P<0.0001); PD-L1 expression levels were positively correlated with CD80 expression levels in human ovarian cancer (r=0.6152, t-test, P<0.0001); CTLA-4 expression levels were positively correlated with PD-1 expression levels in human ovarian cancer (r=0.6530, t-test, P<0.0001). (d) Kaplan–Meier analysis for miR-424(322) indicates that the patients with samples in which miR-424(322) was highly expressed (50% high), have improved progression-free survival (t-test, P=0.0406). (e,f) Spearman’s rank correlation analysis identified inverse correlations between miR-424(322) and PD-L1 (r=−0.5283, t-test, P=0.0003) and CD80 (r=−0.5180, t-test, P=0.0004) in the ovarian cancer tumour samples.